From the Center
AllSides Media Bias Rating: Center
Kimberly-Clark is laying down $40 billion to buy Kenvue in a massive deal that has puzzled some investors as the Tylenol maker struggles with weak sales, lawsuits and White House attacks linking its painkiller to autism.
Check for Bias
The AI-powered AllSides Bias Checker instantly reveals the bias of a news article. Tap the button to use.
Related Coverage
AllSides Picks
More News about Healthcare
News from the Left
News from the Center
News from the Right
These five states are putting transgender sports, gender-medicine questions before voters next month
Just The News